Cincinnati, OH-November 2, 2009
Medpace has entered into a purchase agreement to acquire Pharma Brains AG, an oncology focused CRO based in Basel, Switzerland.
Pharma Brains is led by Dr. Marc Salzberg, President and CEO, a research professional with extensive experience in oncology Phase I-IV studies as well as drug development and regulatory affairs.
"I am pleased to have Dr. Salzberg joining the group as an integral leader beginning with the integration and going forward as the VP of Oncology, Europe and General Manager, Switzerland," said Dr. August Troendle, President and CEO, Medpace. "Marc Salzberg is a distinguished professional in European drug development and brings 17 years of industry and leadership experience to Medpace."
The integration of Pharma Brains operations will begin immediately with the intent of completing the merger by the end of 2009.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.